<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103673</url>
  </required_header>
  <id_info>
    <org_study_id>102-0035C</org_study_id>
    <nct_id>NCT02103673</nct_id>
  </id_info>
  <brief_title>DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <brief_summary>
    <textblock>
      The population of dementia is increasing rapidly. Cognitive impairment as well as Behavioral
      and psychological symptoms of dementia (BPSD) add heavy burdens to caregiver. NMDA activation
      is critical for learning and memory. Individuals with Alzheimer's disease (AD) have fewer
      NMDA receptors in the frontal cortex and hippocampus than controls. This study is a
      randomized, double-blind, placebo-controlled drug trial. All patients will be allocated
      randomly to two groups: (1) NMDA enhancer: DAOIB (starting dosage: 250-500 mg/day), (2)
      placebo, for 6 weeks. The investigators hypothesize that DAOIB may yield better efficacy than
      placebo for cognitive function and clinical symptoms in patients with BPSD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral Pathology in Alzheimer's Disease Rating Scale</measure>
    <time_frame>weeks 0, 2, 4, 6</time_frame>
    <description>Change from baseline in Behavioral Pathology in Alzheimer's Disease Rating Scale at weeks 2, 4 and 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - cognitive subscale</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <description>Change from baseline in Alzheimer's Disease Assessment Scale - cognitive subscale at week 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatirc Inventory</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <description>Change from baseline in Neuropsychiatirc Inventory at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental Activities of Daily Living</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <description>Changes from baseline in Instrumental Activities of Daily Living at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zarit Caregiver Burden Interview</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <description>Changes from baseline in Zarit Caregiver Burden Interview at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Geriatric Depression Scale</measure>
    <time_frame>weeks 0, 2, 4, 6</time_frame>
    <description>Changes from baseline in Geriatric Depression Scale at weeks 2, 4 and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental Status Examination</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <description>Changes from baseline in Mini-Mental Status Examination at week 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Behavioral and Psychological Symptoms in Alzheimer's Disease</condition>
  <condition>Behavioral and Psychological Symptoms in Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>DAOIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth per day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAOIB</intervention_name>
    <description>Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks</description>
    <arm_group_label>DAOIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention drug: placebo by mouth. Duration: 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of probable Alzheimer's disease or probable vascular dementia

          -  For patients with vascular dementia, the post-stroke period must be more than 3 months

          -  Mini-Mental State scores between 5-26

          -  Clinical Dementia Rating score equal to or greater than 1

          -  Behavioral Pathology in Alzheimer's Disease Rating Scale score equal to or greater
             than 2

        Exclusion Criteria:

          -  Current substance abuse or history of substance dependence in the past 6 months

          -  Other major psychiatric diagnoses, such as schizophrenia, major depressive disorder,
             bipolar disorder and mental retardation etc.

          -  Serious medical or neurological illness other than Alzheimer's disease/vascular
             dementia and other secondary dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsien-Yuan Lane, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>China Medical University Hospital,Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chieh-Hsin Lin</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

